Very well-tolerated therapy with impressive clinical and laboratorial improvement of this uncommon disease process.
Another study showing that ctDNA will absolutely change how we manage and follow patients in a myriad of neoplasms, with decreased utilization of CT scans in the next decade.
Very interesting study with potential practical use of MRD surveillance instead of expensive maintenance therapies with toxicities for patients with lower risk disease from a genomic standpoint. Larger studies may be needed to confirm this strategy.
Interesting lack of deepened response with chemotherapy intensification. Expected increase in GI toxicity, increased cost and diminished options upon progression place this truly a quadruple combination on the shelf.
Impressive response rates and complete response in this setting, with moderate toxicities. Randomized trial is necessary to document survival, PFS differences. Cost will be very considerable in the setting value-based strategies. The clinical benefit must be quite superior in a randomized setting.
Fascinating report/study making salient points on the continued need to characterize patients’ neoplasm from a genomic standpoint and the impact of direct management of oligometastatic disease in patients with high-risk mutational signature.
While price transparency across sites of care on its face is a step in the right direction, datapoints when viewed discretely are less informative when it comes to the actual costs associated with cancer care. Additional work, analysis and research is much needed across the stakeholder continuum to fully understand the costs associated with the treatment of cancer, and to further achieve the transparency goals set forth by CMS in 2019 with this initiative.
STAT News published the below Op Ed from COA that does that highlights the dysfunction of the 340B system and how Hospital Systems and PBMs are profiting Billions of dollars a year off of a program that was intended to help underserved patients. Is a great “high level” review to help understand the overall impact on the US medical system and the importance of health care reform in this area.
The combination of cabozantinib/nivolumab remains a powerful combination in the RCC space. This article brings together data on histology and genomics to predict response in NCC-RCC with improved efficacy in tumors expressing NF2 and FH, and decreased activity in chromophobic histology. The role and utilization of data continue to evolve and become prevalent in day-to-day practice.
Again, further evidence of continued efficacy and tolerability of IO and IO/chemotherapy in SCCHN as compared to EGFR-blockade/chemotherapy. The PD-L1 negative space remains a more difficult scenario, hence new biomarkers are critically important. The long-term response and CR of a percentage of patients are real and intriguing (patient characteristics leading to such response).
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
